Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma

被引:17
|
作者
Wang, Wenjuan [1 ]
Ye, Yingquan [2 ]
Zhang, Xuede [1 ]
Ye, Xiaojuan [1 ]
Liu, Chaohui [1 ]
Bao, Lingling [1 ]
机构
[1] Beilun Dist Peoples Hosp, Dept Hematol & Oncol, Ningbo, Peoples R China
[2] Anhui Med Univ, Affiliated Hosp 1, Oncol Dept Integrated Tradit Chinese & Western Med, Hefei, Peoples R China
关键词
necroptosis; lncRNA; hepatocellular carcinoma; immune infiltration; prognosis; LNCRNA; RESISTANCE; EXPRESSION;
D O I
10.3389/fmolb.2022.937979
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Necroptosis is a form of programmed cell death, and studies have shown that long non-coding RNA molecules (lncRNAs) can regulate the process of necroptosis in various cancers. We sought to screen lncRNAs associated with necroptosis to predict prognosis and tumor immune infiltration status in patients with hepatocellular carcinoma (HCC).Methods: Transcriptomic data from HCC tumor samples and normal tissues were extracted from The Cancer Genome Atlas database. Necroptosis-associated lncRNAs were obtained by co-expression analysis. Necroptosis-associated lncRNAs were then screened by Cox regression and least absolute shrinkage and selection operator methods to construct a risk model for HCC. The models were also validated and evaluated by Kaplan-Meier analysis, univariate and multivariate Cox regression, and time-dependent receiver operating characteristic (ROC) curves. In addition, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes enrichment, gene set enrichment, principal component, immune correlation, and drug sensitivity analyses were applied to assess model risk groups. To further differentiate the immune microenvironment of different HCC subtypes, the entire dataset was divided into three clusters, based on necroptosis-associated lncRNAs, and a series of analyses performed.Results: We constructed a model comprising four necroptosis-associated lncRNAs: POLH-AS1, DUXAP8, AC131009.1, and TMCC1-AS1. Overall survival (OS) duration was significantly longer in patients classified as low-risk than those who were high-risk, according to our model. Univariate and multivariate Cox regression analyses further confirmed risk score stability. The analyzed models had area under the ROC curve values of 0.786, 0.713, and 0.639 for prediction of 1-, 3-, and 5-year OS, respectively, and risk score was significantly associated with immune cell infiltration and ESTIMATE score. In addition, differences between high and low-risk groups in predicted half-maximal inhibitory concentration values for some targeted and chemical drugs, providing a potential basis for selection of treatment approach. Finally, cluster analysis facilitated more refined differentiation of the immune microenvironment in patients with HCC and may allow prediction of the effectiveness of immune checkpoint inhibitors.Conclusions: This study contributes to understanding of the function of necroptosis-related lncRNAs in predicting the prognosis and immune infiltration status of HCC. The risk model constructed and cluster analysis provide a basis for predicting the prognosis of patients with HCC and to inform the selection of immunotherapeutic strategies.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Inflammatory Response-Related Long Non-Coding RNA Signature Predicts the Prognosis of Hepatocellular Carcinoma
    Li, Xinyu
    Zhang, Shuqiao
    Zhang, Shijun
    Kuang, Weihong
    Tang, Chunzhi
    [J]. JOURNAL OF ONCOLOGY, 2022, 2022
  • [2] Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma
    Cao, Jie
    Wu, Lili
    Lei, Xin
    Shi, Keqing
    Shi, Liang
    Shi, Yifen
    [J]. BIOENGINEERED, 2021, 12 (01) : 673 - 681
  • [3] Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma
    Lu, Jing
    Wang, Haoyu
    Cao, Wanyue
    Chen, Desheng
    He, Zeping
    Xu, Junming
    [J]. HUMAN CELL, 2023, 36 (02) : 712 - 724
  • [4] Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma
    Jing Lu
    Haoyu Wang
    Wanyue Cao
    Desheng Chen
    Zeping He
    Junming Xu
    [J]. Human Cell, 2023, 36 : 712 - 724
  • [5] Deciphering the Role of Necroptosis-Related Long Non-coding RNAs in Hepatocellular Carcinoma: A Necroptosis-Related lncRNA-Based Signature to Predict the Prognosis of Hepatocellular Carcinoma
    Ye, Gao-Qi
    Wang, Ming-Da
    Diao, Yong-Kang
    Li, Chao
    Yao, Lan-Qing
    Gu, Li-Hui
    Xu, Jia-Hao
    Yang, Tian
    Tong, Xiang-Min
    [J]. APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2024,
  • [6] Prognostic Value of an Immune Long Non-Coding RNA Signature in Liver Hepatocellular Carcinoma
    Kong, Rui
    Wang, Nan
    Zhou, Chun li
    Lu, Jie
    [J]. JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2024, 34 (04) : 958 - 968
  • [7] A novel necroptosis-related long non-coding RNA signature predicts prognosis and immune response in cervical cancer patients
    Kong, Xiaoyu
    Xiong, Yuanpeng
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 12947 - 12964
  • [8] A novel necroptosis-related long non-coding RNA signature predicts prognosis and immune response in cervical cancer patients
    Xiaoyu Kong
    Yuanpeng Xiong
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 12947 - 12964
  • [9] Establishment of a novel signature to predict prognosis and immune characteristics of pancreatic cancer based on necroptosis-related long non-coding RNA
    Xiong, Yuanpeng
    Kong, Xiaoyu
    Fang, Kang
    Sun, Gen
    Tu, Shuju
    Wei, Yongyang
    Ouyang, Yonghao
    Wan, Renhua
    Xiao, Weidong
    [J]. MOLECULAR BIOLOGY REPORTS, 2023, 50 (09) : 7405 - 7419
  • [10] Establishment of a novel signature to predict prognosis and immune characteristics of pancreatic cancer based on necroptosis-related long non-coding RNA
    Yuanpeng Xiong
    Xiaoyu Kong
    Kang Fang
    Gen Sun
    Shuju Tu
    Yongyang Wei
    Yonghao Ouyang
    Renhua Wan
    Weidong Xiao
    [J]. Molecular Biology Reports, 2023, 50 : 7405 - 7419